Amphastar Pharmaceuticals (AMPH) Receivables - Other (2022 - 2026)

Amphastar Pharmaceuticals has reported Receivables - Other for 5 years, with the latest figure at $900000.0 in Q2 2026.

• On a quarterly basis, Receivables - Other rose 80.0% year-over-year to $900000.0 in Q2 2026; TTM through Jun 2026 was $900000.0, a 80.0% increase from a year earlier, with the FY2024 full-year figure at $200000.0, changed N/A from the prior year.
• Receivables - Other was $900000.0 for Q2 2026 at Amphastar Pharmaceuticals, up from $700000.0 in the prior quarter.
• The five-year high for Receivables - Other was $900000.0 in Q2 2026, with the low at $200000.0 in Q3 2022.
• Average Receivables - Other over 5 years is $400000.0, with a median of $350000.0 recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: Receivables - Other plunged 33.33% in 2025, then surged 250.0% in 2026.
• Over 5 years, Receivables - Other stood at $400000.0 in 2022, then slumped by 50.0% to $200000.0 in 2023, then changed by 0.0% to $200000.0 in 2024, then surged by 150.0% to $500000.0 in 2025, then surged by 80.0% to $900000.0 in 2026.
• The last three Receivables - Other figures came in at $900000.0 (Q2 2026), $700000.0 (Q1 2026), and $500000.0 (Q3 2025), per Business Quant data.